Adipokines and thrombosis

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 12, 2011, Pages 864-871

  Schäfer, Katrin ^a   Konstantinides, Stavros ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Adipokines; Atherosclerosis; Inflammation; Obesity; Thrombosis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CYCLIC AMP; CYCLIC GMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; ILOPROST; INTEGRIN; INTEGRIN ALPHA2B BETA3; LEPTIN; NITRIC OXIDE; PADGEM PROTEIN; PHOSPHOLIPASE A2; PHOSPHOLIPASE C GAMMA2; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROSTACYCLIN I2; PROTEIN KINASE C; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FIBRINOLYSIS; HEART INFARCTION; LUNG EMBOLISM; MEDICAL SOCIETY; MONOCYTE; NEUTROPHIL; NONHUMAN; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RISK FACTOR; STENT THROMBOSIS; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BLOOD PLATELETS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; EPOPROSTENOL; FEMALE; HUMANS; MALE; MICE; NEUTROPHILS; NITRIC OXIDE; OBESITY; P-SELECTIN; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; THROMBOPLASTIN; THROMBOSIS;

EID: 82355183520     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05589.x     Document Type: Article

References (87)

1. Eckel RH, Krauss RM. American Heart Association call to action: Obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998; 97: 2099-100.
2. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N. Engl. J. Med. 2011; 364: 1746-60.
3. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health 2009; 9: 88.
4. Wolk R, Berger P, Lennon RJ, Brilakis ES, Somers VK. Body mass index: A risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation 2003; 108: 2206-11.
5. Wang ZJ, Zhou YJ, Liu YY et al. Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents. Heart 2009; 95: 1587-92.
6. Sarno G, Garg S, Onuma Y et al. The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). Am. J. Cardiol. 2010; 105: 475-9.
7. Borch KH, Braekkan SK, Mathiesen EB et al. Anthropometric measures of obesity and risk of venous thromboembolism: The Tromso study. Arterioscler. Thromb. Vasc. Biol. 2010; 30: 121-7.
8. Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: Results from the Copenhagen City Heart Study. Circulation 2010; 121: 1896-903.
9. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation 2008; 117: 93-102.
10. Eichinger S, Hron G, Bialonczyk C et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch. Intern. Med. 2008; 168: 1678-83.
11. Nagai N, Hoylaerts MF, Cleuren AC, van Vlijmen BJ, Lijnen HR. Obesity promotes injury induced femoral artery thrombosis in mice. Thromb. Res. 2008; 122: 549-55.
12. Cleuren AC, Van Hoef B, Hoylaerts MF, van Vlijmen BJ, Lijnen HR. Short-term ethinyl estradiol treatment suppresses inferior caval vein thrombosis in obese mice. Thromb. Haemost. 2009; 102: 993-1000.
13. Vachharajani V, Russell JM, Scott KL et al. Obesity exacerbates sepsis-induced inflammation and microvascular dysfunction in mouse brain. Microcirculation 2005; 12: 183-94.
14. Terao S, Yilmaz G, Stokes KY, Ishikawa M, Kawase T, Granger DN. Inflammatory and injury responses to ischemic stroke in obese mice. Stroke 2008; 39: 943-50.
15. Nishimura S, Manabe I, Nagasaki M et al. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J. Clin. Invest. 2008; 118: 710-21.
16. Rosito GA, D'Agostino RB, Massaro J et al. Association between obesity and a prothrombotic state: The Framingham Offspring Study. Thromb. Haemost. 2004; 91: 683-9.
17. Hankey CR, Rumley A, Lowe GD, Woodward M, Lean ME. Moderate weight reduction improves red cell aggregation and factor VII activity in overweight subjects. Int. J. Obes. Relat. Metab. Disord. 1997; 21: 644-50.
18. Murakami T, Horigome H, Tanaka K et al. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb. Res. 2007; 119: 45-53.
19. Davi G, Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 2007; 357: 2482-94.
20. Samocha-Bonet D, Justo D, Rogowski O et al. Platelet counts and platelet activation markers in obese subjects. Mediators Inflamm. 2008; 2008: 834153.
21. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int. J. Clin. Pract. 2005; 59: 981-2.
22. Slavka G, Perkmann T, Haslacher H et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 2011; 31: 1215-8.
23. Muscari APS, Cenni A, Ludovico C et al. Determinants of mean platelet volume (MPV) in an elderly population: Relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb. Haemost. 2008; 99: 1079-84.
24. Bordeaux BC, Qayyum R, Yanek LR et al. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev. Cardiol. 2010; 13: 56-62.
25. Dellas C, Schäfer K, Rohm I et al. Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. Thromb. Haemost. 2008; 100: 1123-9.
26. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int. J. Obes. Relat. Metab. Disord. 2003; 27: 907-11.
27. Anfossi G, Russo I, Massucco P et al. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: Possible role in platelet hyperactivation in obesity. Eur. J. Clin. Invest. 2004; 34: 482-9.
28. Russo I, Del Mese P, Doronzo G et al. Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. Clin. Chem. 2007; 53: 1053-60.
29. Raffaelli F, Nanetti L, D'Angelo M et al. Interactions between lipoproteins and platelet membranes in obesity. Obesity 2009; 17: 1375-80.
30. Raju J, Bajaj G, Chrusch J, Bird RP. Obese state leads to elevated levels of TGF-beta and COX isoforms in platelets of Zucker rats. Mol. Cell. Biochem. 2006; 284: 19-24.
31. Russo I, Traversa M, Bonomo K et al. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity 2010; 18: 788-97.
32. Hanzu FA, Palomo M, Kalko SG et al. Translational evidence of endothelial damage in obese individuals: Inflammatory and prothrombotic responses. J. Thromb. Haemost. 2011; 9: 1236-45.
33. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011; 11: 85-97.
34. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 2005; 96: 939-49.
35. Qasim A, Mehta NN, Tadesse MG et al. Adipokines, insulin resistance, and coronary artery calcification. J. Am. Coll. Cardiol. 2008; 52: 231-6.
36. Soderberg S, Colquhoun D, Keech A et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: Results from the LIPID study. Int. J. Obes. 2009; 33: 123-30.
37. Konstantinides S, Schäfer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J. Clin. Invest. 2001; 108: 1533-40.
38. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, Eitzman DT. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2005; 25: E119-22.
39. Konstantinides S, Schäfer K, Neels JG, Dellas C, Loskutoff DJ. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 2196-201.
40. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen YC, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002; 287: 1706-9.
41. Dellas C, Schäfer K, Rohm IK et al. Leptin signalling and leptin-mediated activation of human platelets: Importance of JAK2 and the phospholipases Cgamma2 and A2. Thromb. Haemost. 2007; 98: 1063-71.
42. Corsonello A, Malara A, De Domenico D et al. Identifying pathways involved in leptin-dependent aggregation of human platelets. Int. J. Obes. Relat. Metab. Disord. 2004; 28: 979-84.
43. Elbatarny HS, Maurice DH. Leptin-mediated activation of human platelets. Involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex. Am. J. Physiol. Endocrinol. Metab. 2005; 289: E695-702.
44. Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog. Horm. Res. 2004; 59: 305-31.
45. Sugiyama C, Ishizawa M, Kajita K et al. Platelet aggregation in obese and diabetic subjects: Association with leptin level. Platelets 2007; 18: 128-34.
46. Corsonello A, Perticone F, Malara A et al. Leptin-dependent platelet aggregation in healthy, overweight and obese subjects. Int. J. Obes. Relat. Metab. Disord. 2003; 27: 566-73.
47. Corica F, Corsonello A, Perticone F. Effects of leptin on platelet function in obese patients. JAMA 2002; 288: 313-4.
48. Giandomenico G, Dellas C, Czekay RP, Koschnick S, Loskutoff DJ. The leptin receptor system of human platelets. J. Thromb. Haemost. 2005; 3: 1042-9.
49. Rafail S, Ritis K, Schaefer K et al. Leptin induces the expression of functional tissue factor in human neutrophils and peripheral blood mononuclear cells through JAK2-dependent mechanisms and TNFalpha involvement. Thromb. Res. 2008; 122: 366-75.
50. Napoleone EDI, Santo A, Amore C et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: A possible link between obesity and cardiovascular risk? J. Thromb. Haemost. 2007; 5: 1462-8.
51. Cirillo P, Angri V, De Rosa S et al. Pro-atherothrombotic effects of leptin in human coronary endothelial cells. Thromb. Haemost. 2010; 103: 1065-75.
52. Singh P, Peterson TE, Barber KR et al. Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells. Biochem. Biophys. Res. Commun. 2010; 392: 47-52.
53. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131-5.
54. Bjorntorp P. 'Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-6.
55. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: Linking obesity to vascular inflammation. J. Am. Coll. Cardiol. 2005; 46: 1112-3.
56. Glynn RJ, Danielson E, Fonseca FA et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 2009; 360: 1851-61.
57. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359: 2195-207.
58. Danenberg HD, Szalai AJ, Swaminathan RV et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108: 512-5.
59. Tennent GA, Hutchinson WL, Kahan MC et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis 2008; 196: 248-55.
60. Yaron G, Brill A, Dashevsky O et al. C-Reactive protein promotes platelet adhesion to endothelial cells: A potential pathway in atherothrombosis. Br. J. Haematol. 2006; 134: 426-31.
61. Pepys MB, Hawkins PN, Kahan MC et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ. Res. 2005; 97: E97-103.
62. Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-Reactive protein enhances tissue factor expression by vascular smooth muscle cells: Mechanisms and in vivo significance. Arterioscler. Thromb. Vasc. Biol. 2008; 28: 698-704.
63. Samad F, Pandey M, Loskutoff DJ. Regulation of tissue factor gene expression in obesity. Blood 2001; 98: 3353-8.
64. Yamamoto K, Shimokawa T, Yi H et al. Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse. Blood 2002; 100: 4011-8.
65. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. Proc. Natl Acad. Sci. USA 1998; 95: 7591-6.
66. Landin K, Stigendal L, Eriksson E et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39: 1044-8.
67. Shimomura I, Funahashi T, Takahashi M et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat. Med. 1996; 2: 800-3.
68. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol. Med. 1996; 2: 568-82.
69. Vague P, Juhan-Vague I, Aillaud MF et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-3.
70. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb. Haemost. 1997; 78: 656-60.
71. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 2000; 95: 577-80.
72. Konstantinides S, Schäfer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation 2001; 103: 576-83.
73. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000; 96: 4212-5.
74. Schäfer K, Müller K, Hecke A et al. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 2097-103.
75. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-6.
76. Nagai N, Van Hoef B, Lijnen HR. Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice. J. Thromb. Haemost. 2007; 5: 1726-31.
77. Achike FI, To NH, Wang H, Kwan CY. Obesity, metabolic syndrome, adipocytes and vascular function: A holistic viewpoint. Clin. Exp. Pharmacol. Physiol. 2011; 38: 1-10.
78. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: A key adipocytokine in metabolic syndrome. Clin. Sci. 2006; 110: 267-78.
79. Dunajska K, Milewicz A, Jedrzejuk D et al. Plasma adiponectin concentration in relation to severity of coronary atherosclerosis and cardiovascular risk factors in middle-aged men. Endocrine 2004; 25: 215-21.
80. Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: Data from the SAPHIR Study. Stroke 2005; 36: 2577-82.
81. Matsuda M, Shimomura I, Sata M et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J. Biol. Chem. 2002; 277: 37487-97.
82. Okamoto Y, Kihara S, Ouchi N et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-70.
83. Kato H, Kashiwagi H, Shiraga M et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 224-30.
84. Restituto P, Colina I, Varo JJ, Varo N. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 2010; 298: E1072-7.
85. Wang WQ, Zhang HF, Gao GX, Bai QX, Li R, Wang XM. Adiponectin inhibits hyperlipidemia-induced platelet aggregation via attenuating oxidative/nitrative stress. Physiol. Res. 2011; 60: 347-54.
86. Shoji T, Koyama H, Fukumoto S et al. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis 2006; 188: 190-5.
87. Gavrila A, Chan JL, Yiannakouris N et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: Cross-sectional and interventional studies. J. Clin. Endocrinol. Metab. 2003; 88: 4823-31.